...
首页> 外文期刊>Critical reviews in oncology/hematology >Toll-like receptors in lymphoid malignancies: Double-edged sword
【24h】

Toll-like receptors in lymphoid malignancies: Double-edged sword

机译:淋巴恶性肿瘤中的Toll样受体:双刃剑

获取原文
获取原文并翻译 | 示例
           

摘要

Toll-like receptors (TLRs) are the best characterized pattern recognition receptors (PRRs), which play an essential role in the recognition of invading pathogens via specific microbial molecular motifs, comprising a bridge between the innate and adaptive immune responses. Toll-like receptors expression is determined in both normal immune cells and malignant cells, with a distinctive pattern compared to each other, rendering them plausible targets for cancer therapy. Improved molecular profiling of lymphoid malignancies may give new insights into pathogenesis of these cancers and pave the way for novel therapeutic agents, including TLR agonists. In the current review, we summarize the immunopathogenic roles of TLRs in B cell and T cell lymphomas, acute lymphoblastic leukemia, multiple myeloma, and chronic lymphocytic leukemia, as well as the results of studies on TLR ligands and their future implications to manage these hematologic malignancies.
机译:Toll样受体(TLR)是特征最鲜明的模式识别受体(PRR),在通过特定微生物分子基序识别入侵病原体的过程中起着至关重要的作用,其中包括固有免疫反应和适应性免疫反应之间的桥梁。在正常的免疫细胞和恶性细胞中都确定了Toll样受体的表达,彼此之间具有独特的模式,从而使它们成为癌症治疗的合理靶标。改善的淋巴恶性肿瘤的分子谱分析可以为这些癌症的发病机理提供新的见识,并为包括TLR激动剂在内的新型治疗药物铺平道路。在本综述中,我们总结了TLR在B细胞和T细胞淋巴瘤,急性淋巴细胞白血病,多发性骨髓瘤和慢性淋巴细胞性白血病中的免疫致病作用,以及TLR配体的研究结果及其对管理这些血液学的未来意义恶性肿瘤。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号